79 results on '"Triggiani, Massimo"'
Search Results
2. Low-grade endotoxemia and risk of recurrent thrombosis in primary antiphospholipid syndrome. The multicenter ATHERO-APS study
3. MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
4. POSTER: MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial
5. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
6. Thymic stromal lymphopoietin (TSLP) is a substrate for tryptase in patients with mastocytosis
7. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
8. Identifying and managing those at risk for vaccine related allergy and anaphylaxis
9. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
10. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis
11. Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis
12. Avapritinib Improved Symptoms and Quality of Life in Patients With Indolent Systemic Mastocytosis in the PIONEER Study
13. Efficacy and Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Results from the Double Blinded Placebo-Controlled PIONEER Study
14. Risk of Death, Thrombotic and Hemorrhagic Events in Patients with Atrial Fibrillation and Systemic Autoimmune Diseases. An Analysis from a Global Federated Dataset
15. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
16. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
17. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
18. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
19. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond
20. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
21. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
22. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
23. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study
24. Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma
25. Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study
26. Severe asthma: One disease and multiple definitions
27. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
28. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis
29. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
30. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
31. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
32. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
33. International Consensus on the Use of Genetics in the Management of Hereditary Angioedema
34. PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy
35. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study
36. Flow-mediated dilation shows impaired endothelial function in patients with mastocytosis
37. Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression analysis
38. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
39. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology
40. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
41. The role of mast cell-derived secreted phospholipases A2 in respiratory allergy
42. Mast cell activation syndrome: Importance of consensus criteria and call for research
43. Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice
44. Hereditary Angioedema with Normal C1 Inhibitor: An Italian Case Series
45. An International Registry for Angioedema without Urticaria
46. Mast cells as effector cells of innate immunity and regulators of adaptive immunity
47. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
48. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases
49. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
50. Hereditary Angioedema with Normal C1 Inhibitor: An Italian Survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.